Nitrogen, Other Than Nitro Or Nitroso, Bonded Indirectly To Phosphorus Patents (Class 514/114)
  • Patent number: 10953021
    Abstract: Provided herein are compositions and methods for treating or preventing a skin disease or skin condition on the skin of a subject by administering a topical flunisolide composition comprising a therapeutically effective amount of flunisolide and a solubilizing agent that solubilizes the flunisolide.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 23, 2021
    Assignee: Lupin Limited
    Inventors: Douglas Anthony Bakan, Steven B. Newhard, Nilendu Sen, Amol Subhash Mandhare, Tushar Deoram Jadhav, Mukesh Kumar
  • Patent number: 10927067
    Abstract: The present invention specifically relates to novel salt and crystalline form of haloacetic acid and its process of preparation. The invention more particularly relates to novel crystalline form dichloroacetate tromethamine salt and its process of preparation. The present invention more specifically relates to the dichloroacetate tromethamine salt, its process and its use for the treatment of various diseases and/or disorders.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: February 23, 2021
    Inventors: Sarin Parayil, Anil Roy
  • Patent number: 10906923
    Abstract: The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by or associated with TLR7 and/or TLRS, e.g., cancer, graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, and immunodeficiency.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: February 2, 2021
    Assignee: CanWell Biotech Limited
    Inventor: Ninghui Yu
  • Patent number: 10906904
    Abstract: The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: February 2, 2021
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, John Unitt, Timothy Phillips, Benoit Gourdet, Lorna Duffy
  • Patent number: 10898455
    Abstract: A topical cream may include urea and one or more additional active agents such as fluticasone, itraconazole, and mupirocin. The topical cream may be formulated as a lotion, gel, ointment, foam, cream, or emulsion.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: January 26, 2021
    Assignee: CMPD Licensing, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10903522
    Abstract: Phosphonate based lithium complexes of formula (I) and their use in electrolyte compositions for electrochemical cells.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: January 26, 2021
    Assignee: BASF SE
    Inventors: Johannes David Hoecker, Manuel Alejandro Mendez Agudelo, Ryosuke Takeuchi, Frederick Francois Chesneau, Jinbum Kim, Kazuki Yoshida
  • Patent number: 10759994
    Abstract: The present invention provides a luminogenic, in particular a phosphorogenic transition metal-based pyridyl complex containing a nitrone moiety, which nitrone moiety acts as a bioorthogonal functional group and an emission quencher, and can undergo cycloaddition reaction with a complementary bioorthogonal functional group coupled to a substrate. The transition metal is can be selected from iridium or ruthenium. Also disclosed is a method for preparing the transition metal-based pyridyl complex and a pharmaceutical composition comprising it. Still further provided is a method for bioorthogonal labeling of a biomolecule, a method for staining of a cell structure, a method for in vivo imaging of an organism, and a kit for in vivo imaging of an organism. The luminogenic properties and high reactivity of the complexes are highly advantageous for bioorthogonal labeling and imaging of biomolecules in their native biological environments at much lower costs than those of the existing commercial products.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 1, 2020
    Assignee: City University of Hong Kong
    Inventors: Kam Wing Kenneth Lo, Hua Wei Liu, Cho Cheung Lee, Siu Ming Tang
  • Patent number: 10668091
    Abstract: To provide a multidrug-resistant Gram positive bacteria antibacterial agent containing as an active ingredient a novel component to which multidrug-resistant bacteria are not resistant, and an external agent containing the same. The multidrug resistant Gram-positive bacteria antibacterial agent according to the present invention contains an amphipathic compound having an HLB value of greater than 9.5 and 20 or less and an acyl group as an active ingredient. The external agent according to the present invention contains the multidrug resistant Gram-positive bacteria antibacterial agent.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: June 2, 2020
    Assignee: KEWPIE CORPORATION
    Inventors: Marie Kozono, Hideto Yoshida
  • Patent number: 10660899
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 26, 2020
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Patent number: 10299714
    Abstract: Disclosed are devices for collecting and stabilizing blood that contain a blood stabilization agent which includes variegin or an analog thereof, a polysulfated disaccharide, or a combination thereof, each in an amount effective to stabilize blood. Methods of making and using the devices, and kits containing the devices, are also provided.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: May 28, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Craig A. Gelfand, Daniel Marchiarullo, Keith Moskowitz
  • Patent number: 10206936
    Abstract: The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: February 19, 2019
    Assignee: Vascular Biogenics Ltd.
    Inventors: Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Patent number: 10202331
    Abstract: The present invention provides novel and antifibrinolytic compounds, processes for their preparation, pharmaceutical and veterinary compositions thereof, and their use in medicine, in particular for the treatment of bleeding. The present application relates to numerous embodiments of chemical structures which in whole or in part mimic or are analogs of the amino acid Lysine such that they bind to specific binding site(s) within specific protein sub structures in the structures of Plasminogen, and/or Plasmin, and/or Plasminogen Activators, and/or Thrombin.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: February 12, 2019
    Inventor: Bakshy A. Chibber
  • Patent number: 10166301
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: January 1, 2019
    Assignee: CANCER TARGETED TECHNOLOGY LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Patent number: 10154668
    Abstract: The invention relates to quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds, processes for preparing quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds, antimicrobial coating compositions comprising quaternary ammonium multi-dentate mono-, bis-, tris- and tetrakis-phosphonate compounds and method of treating a surface with said compositions to provide a durable, antimicrobial-treated surface.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: December 18, 2018
    Assignee: Nano Safe Coatings Incorporated
    Inventors: Lukasz Porosa, Gideon Wolfaardt, Daniel Foucher
  • Patent number: 10130576
    Abstract: The present invention relates to oral compositions, comprising select phospholipid surfactants. Methods for using the compositions are also disclosed.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: November 20, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Patricia L. Golas, Carolyn J. Mordas
  • Patent number: 10106778
    Abstract: Aspects of the invention relate to methods and related compositions for preferentially targeting cancer stem cells. In some embodiments, the methods utilize PKC-?/FRA1 pathway inhibitors to target carcinoma cells. Also provided are methods for identifying a candidate compound for selectively inhibiting growth of cancer stem cell, and methods for obtaining cells that have undergone an epithelial to mesenchymal transition.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 23, 2018
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Wai Leong Tam, Robert A. Weinberg
  • Patent number: 10034847
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: July 31, 2018
    Assignee: Quadriga Biosciences, Inc.
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller
  • Patent number: 10022388
    Abstract: The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: July 17, 2018
    Assignee: Vascular Biogenics Ltd.
    Inventors: Itzhak Mendel, Yaniv Salem, Niva Yacov, Eyal Breitbart
  • Patent number: 9974869
    Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: May 22, 2018
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
  • Patent number: 9963415
    Abstract: The present invention provides compositions and method for production of shikimic acid based on extracts obtained from oil palm-based materials, and more particularly oil palm based waste materials and by-products. The method includes purifying shikimic acid from extracts comprising oil palm phenolics (OPP).
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: May 8, 2018
    Assignee: Malaysian Palm Oil Board
    Inventors: Sambandan Tg, Chokyun Rha, Ravigadevi Sambanthamurthi, Anthony J Sinskey, Yew Ai Tan, Kalyana Sundram P. Manickam, Mohd Basri Wahid
  • Patent number: 9931331
    Abstract: The present invention relates to an anticancer supplement containing loperamide as an active ingredient. More specifically, a proteasome inhibitor alone cannot exhibit an anticancer effect on solid cancers and some blood cancers, but when the proteasome inhibitor and loperamide are co-administered or a composition containing the proteasome inhibitor and loperamide is provided, cancer cell death by the proteasome inhibitor can be effectively induced, thereby exhibiting an improved anticancer effect, and enhancing anticancer effects on solid cancers and blood cancers while reducing side effects caused by a high-concentration of the proteasome inhibitor. Therefore, the composition containing the proteasome inhibitor and loperamide as active ingredients, according to the present invention, can be useful for preventing or treating cancer, and loperamide can be provided as an anticancer supplement when the proteasome inhibitor is used to treat cancer.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: April 3, 2018
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUN DATION
    Inventors: Kyeong Sook Choi, In Young Kim, Mi Jin Yoon, A Reum Lee
  • Patent number: 9889110
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: February 13, 2018
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James T. Dalton, Duane D. Miller
  • Patent number: 9877976
    Abstract: Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (CT) radiation. Subjects receiving ionizing radiation may be those persons suspected of having cancer, or cancer patients having received or currently receiving cancer therapy, and or those patients having received previous ionizing radiation, including those who are approaching or have exceeded the recommended total radiation dose for a person.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: January 30, 2018
    Assignee: The University of Chicago
    Inventor: David J. Grdina
  • Patent number: 9849126
    Abstract: The present disclosure describes a sterile formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, and antifungal, and an optional anti-inflammatory in a thick, otic carrier. In one embodiment, the sterilization comprises e-beam irradiating ingredients the formulation while heat-sterilizing other ingredients before combining under sterile condition.
    Type: Grant
    Filed: April 25, 2015
    Date of Patent: December 26, 2017
    Assignee: Entrx LLC
    Inventors: Matthew Branch, Vance Oglesbee
  • Patent number: 9801848
    Abstract: The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and/or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 31, 2017
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Anna Di Nardo, Yumiko Muto
  • Patent number: 9781934
    Abstract: Methods for controlling unwanted vegetation, such as weeds, to turfgrass by applying an active compound combination including a triazolinone herbicide, for example, sulfonylamino-carbonyl-triazolinone, and at least one sulfonylurea herbicides, to turfgrass is described herein. The disclosure also provides for active compound combinations and methods of improving turfgrass quality.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: October 10, 2017
    Assignee: BAYER CROPSCIENCE LP
    Inventors: Bruce Spesard, Don Myers, Laurence Mudge, Matt Bradley
  • Patent number: 9763909
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an ?-(methanesulfonyl)alkenylnitrile compound, or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering an ?-(methanesulfonyl)alkenylnitrile compound or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. The present invention is further directed to a method for potentiating the analgesic effects of morphine, by administering an effective amount of 3-(methylsulfonyl)acrylonitrile to a subject who is being treated with morphine and is suffering from pain. Oral and topical administration are preferred.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: September 19, 2017
    Assignee: Olatec Therapeutics LLC
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse, George M. Shopp, Jr.
  • Patent number: 9726683
    Abstract: A computer-based method for determining a prediction of risk and/or an indication of extent of coronary stenosis in a human subject, comprises the steps of: (a) inputting the level of at least one cholesteryl ester measured in a blood sample collected from said subject; and then (b) inputting the age and gender of said subject; and then (c) generating in said computer from said cholesteryl ester level input, said age input and said gender input a prediction of risk and/or an indication of extent of coronary stenosis in said subject. Systems and methods are also described.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 8, 2017
    Assignee: Wake Forest University Health Sciences
    Inventors: Lawrence L. Rudel, Chadwick D. Miller, Michael J. Thomas
  • Patent number: 9650346
    Abstract: Disclosed are solid forms of antiretroviral compounds and anti-oxidative acids, and processes for their preparation. Pharmaceutical compositions using the solid forms are also disclosed.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: May 16, 2017
    Assignee: Laurus Labs Private Ltd.
    Inventors: Venkata S. Indukuri, Vamsee K. Muppidi, Sree R. Joga, Seeta R. Gorantla, Satyanarayana Chava
  • Patent number: 9597299
    Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analog, (Z)3,4,5,4?-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analog to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 21, 2017
    Assignee: Macau University of Science and Technology
    Inventors: Lai-Han Leung, Xing-Xing Fan, Liang Liu, Zebo Jiang
  • Patent number: 9566288
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: February 14, 2017
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai
  • Patent number: 9540638
    Abstract: The present invention provides a lipid particle which has low cytotoxicity, can stably hold a nucleic acid molecule outside a cell (in blood), and can escape from an endosome and rapidly release the nucleic acid in the cytoplasm; a nucleic acid transfer carrier; a compound for manufacturing a nucleic acid transfer carrier; a method for manufacturing a lipid particle; and a gene transfer method. The lipid particle contains, as constituents, a phospholipid having one or more amino groups and one or more nitrogen-containing heterocyclic groups, a neutral lipid not containing a nitrogen-containing heterocyclic group, a sterol, and a nucleic acid.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 10, 2017
    Assignee: FUJIFILM Corporation
    Inventors: Naoyuki Nishikawa, Kyoko Senga, Yuuki Inoue, Yuko Igarashi
  • Patent number: 9499485
    Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: November 22, 2016
    Assignee: BIOGEN MA INC.
    Inventors: Kevin Guckian, Gnanasambandam Kumaravel, Bin Ma, Lihong Sun, Zhili Xin, Lei Zhang
  • Patent number: 9492466
    Abstract: The present disclosure provides methods of treating, ameliorating, or preventing immune disorders, allergic disorders, or inflammatory disorders, or combinations thereof, or providing hepatoprotection in subject. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a ?-hydroxy-?-aminophosphonate or ?-amino-?-aminophosphonate.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 15, 2016
    Assignee: Nucitec S.A. de C.V.
    Inventors: Ricardo Abraham De La Cruz Cordero, Jorge Luis Rosado Loria, Miguel Angel Duarte Vazquez, José Mario Ordóñez Palacios, Jorge Alberto Reyes Esparza, Maria de Lourdes Rodriguez Fragoso
  • Patent number: 9439879
    Abstract: Urinary incontinence is treated by administration of pharmaceutical compositions containing at least one nitrone spin trap such as ?-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and methods of treatment further include at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and polyenylphosphatidylcholine.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: September 13, 2016
    Inventor: Nicholas V. Perricone
  • Patent number: 9399653
    Abstract: Described herein are the preparation and use of novel bromo-phosphonomethylphenylalanine amino acid derivatives (BrPmp) and BrPmp-containing peptides as specific, irreversible protein tyrosine phosphatase inhibitors, which are suitable for application in peptide synthesis. These derivatives are particularly advantageous since their synthesis is both easy and scalable, and they are suitable for peptide synthesis. The BrPmp derivatives described herein can be appropriately protected to allow for solid phase peptide synthesis (SPPS) and incorporation into peptides for preparation of protein tyrosine phosphatase inhibitors and inhibitor libraries. The peptides and peptide libraries can be used to identify new protein tyrosine phosphatase specific sequences and profile protein tyrosine phosphatase activity in cell lysates, diagnostic samples and biopsy samples.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: July 26, 2016
    Assignee: The Governors of the University of Alberta
    Inventors: Christopher Warren Cairo, Naresh Singh Tulsi, Alan Michael Downey
  • Patent number: 9381204
    Abstract: The present invention describes and claims stable pharmaceutical compositions and/or food supplements based on phosphatidylserine (PS) and curcumin, which are consequently devoid of degradation products, for use in the prevention and treatment of disorders associated with brain aging, and in the prevention and treatment of osteoporosis and/or osteoarthritis.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: July 5, 2016
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Giovanni Gennari, Susi Panfilo
  • Patent number: 9370576
    Abstract: The invention relates to the field of pharmaceutics, in particular, to solid pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or pharmaceutically acceptable salt thereof, stabilizer, lubricant and filler; to method for preparation of pharmaceutical composition, to medicaments for immune suppression and treating multiple sclerosis. 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol represents an immune modulator, which causes redistribution of lymphocytes from blood flow into secondary lymphoid tissue that leads to immune suppression. The invention provides uniform distribution of the active ingredient in the solid composition, high stability and improved flowability of the solid pharmaceutical composition. Due to the improved flowability the compositions suggested in the invention can be used on automated equipment.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: June 21, 2016
    Inventors: Alexandre Vasilievich Ivachtchenko, Alexandre Viktorovich Demin
  • Patent number: 9340527
    Abstract: Compounds of formula (I) or (II) can modulate the activity of SIP receptors.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: May 17, 2016
    Assignee: Biogen MA Inc.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Kevin Guckian, Gnanasambandam Kumaravel
  • Patent number: 9279085
    Abstract: The invention relates to a method for producing monofunctionalized dialkylphosphinic acids, esters, and salts, characterized in that a phosphinic acid source (I) is reacted with olefins (IV) in the presence of a catalyst A to obtain an alkylphosphonous acid, the salt or ester thereof, whereupon said alkylphosphonous acid, the salt or ester (II) thereof is reacted with compounds containing C?C, C?O, or C?N double bonds to obtain compounds of type (III), wherein R1, R2, R3, R4, R5, R6 are identical or different from each other and independently represent, inter alia, H, C1-C18-alkyl, C6-C18-aryl, C6-C18-aralkyl, X represents, inter alia, H, C1-C18-alkyl, C6-C18-aryl, and/or Mg, Ca, Al, Sb, Sn, Ge, Ti, Fe, Zr, Zn, Ce, Bi, Sr, Mn, Cu, Ni, Li, Na, K, H, and wherein A represents OH, NH2, NHR, NR2, or O—CO—R8, and W represents a mineral acid, carboxylic acid, Lewis acid, or organic acid, wherein n is a whole or a fractional number from 0 to 4, and catalyst A represents transition metals and/or transition metal compo
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: March 8, 2016
    Assignee: Clariant Finance (BVI) Limited
    Inventors: Michael Hill, Harald Bauer, Werner Krause, Martin Sicken
  • Patent number: 9206206
    Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: December 8, 2015
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eti Kovalevski-Ishai, Zeev Ziniuk, Gideon Halperin, Itzhak Mendel, Erez Feige, Niva Yacov, Eyal Breitbart
  • Patent number: 9187413
    Abstract: Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R1 is a polar group. In some embodiments, R1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: November 17, 2015
    Assignees: The Regents of the University of California, Universita Degli Studi Di Parma, Universita Degli Studi Di Urbino
    Inventors: Daniele Piomelli, Jason R. Clapper, Guillermo Moreno-Sanz, Andrea Duranti, Giovanna Guiducci, Marco Mor, Giorgio Tarzia
  • Patent number: 9134330
    Abstract: The object of the present invention is to provide a biomarker which is highly correlated to the conventional biomarkers of metabolic syndrome or life-style related disease in a wide range of subjects to be tested, including subjects of special health check-up aged between 40 and 74, or an advantageous method for detecting metabolic syndrome or life-style related disease. The object can be solved by a method for detecting metabolic syndrome or life-style related disease by measuring the concentration of choline plasmalogen in a sample to be tested.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: September 15, 2015
    Assignees: TEIKYO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, ADEKA CORPORATION
    Inventors: Ryouta Maeba, Hiroshi Hara, Megumi Nishimukai, Yuya Yamazaki, Toru Nezu
  • Patent number: 9114150
    Abstract: Compositions containing one or more bioactive forms of creatine, which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creatinol O-phosphate species to a mammalian subject, either chronically or acutely.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: August 25, 2015
    Assignee: JHO INTELLECTUAL PROPERTY HOLDINGS, LLC
    Inventor: John H. Owoc
  • Publication number: 20150148316
    Abstract: The subject invention includes a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said phospholipid and uses thereof.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 28, 2015
    Inventors: FABIANA BAR YOSEF, DORI PELLED, ARIEL KATZ
  • Patent number: 9034820
    Abstract: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3 (LPA3).
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: May 19, 2015
    Inventor: Hsinyu Lee
  • Patent number: 9005663
    Abstract: An exemplary embodiment of the invention is a method for making silver nanoparticles, and includes steps of reacting a silver salt with a phosphene amino acid to make silver nanoparticles. Exemplary phosphene amino acids include trimers, with a particular example being a trimeric amino acid conjugate containing one phosphene group. In an exemplary method of the invention, the silver nanoparticles may be produced in timer periods of less than about 30 minutes, and at temperatures of less than about 40° C. Other methods of the invention are directed to methods for stabilizing silver nanoparticles.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: April 14, 2015
    Assignee: The Curators of the University of Missouri
    Inventors: Kannan Raghuraman, Kattesh K. Katti
  • Patent number: 8999960
    Abstract: Novel oxidized thiophospholipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. Exemplary oxidized thiophospholipid according to embodiments described herein have the formula: wherein X1, X2, A1, A2, B?, B?, D? and D? are as described herein.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: April 7, 2015
    Assignee: Vascular Biogenics Ltd.
    Inventors: Eyal Breitbart, Eti Kovalevski-Ishai, Erez Feige, Itzhak Mendel, Zeev Ziniuk, Gideon Halperin
  • Patent number: 8993543
    Abstract: [Problem] To provide a diphenyl sulfide derivative which is useful as a pharmaceutical product that has excellent S1P3 antagonist activity. [Solution] The inventors have discovered that a diphenyl sulfide derivative represented by general formula (1) (wherein R1 represents an alkoxy group having 1-6 carbon atoms, R2 represents a propyl group or an allyl group, X represents methylene or an oxygen atom, and Z represents a halogen atom) has excellent S1P3 antagonist activity as a result of extensive researches for the production of a compound that has S1P3 antagonist activity.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: March 31, 2015
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Kumi Ishikawa, Shigeru Koga, Yasushi Kohno, Kiyoshi Fujii, Ken Yoshikawa
  • Publication number: 20150080347
    Abstract: Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.
    Type: Application
    Filed: December 6, 2013
    Publication date: March 19, 2015
    Applicant: NOVARTIS AG
    Inventors: Vivian Georgousis, Wei-Qin Tong